Asymptomatic hyperuricaemia affects~ 20% of the general population in the USA, with
variable rates in other countries. Historically, asymptomatic hyperuricaemia was considered …

Objectives Despite the publication of hundreds of trials on gout and hyperuricemia,
management of these conditions remains suboptimal. We aimed to assess the quality and …

Gout is the most common cause of inflammatory arthritis worldwide. In UK general practice,
the overall prevalence has increased from 1.4% in 1999 to 2.49% in 2012 [1], despite the …

Serum uric acid (UA) is taken up by endothelial cells and reduces the level of nitric oxide
(NO) by inhibiting its production and accelerating its degradation. Cytosolic and plasma …

Background Xanthine oxidase inhibitors (XOI), classified as purine-like (allopurinol and
oxypurinol) and non-purine (febuxostat and topiroxostat) XOI, present antioxidant properties …

Hyperuricemia and gout, the clinical manifestation of monosodium urate crystal deposition,
are common in patients with chronic kidney disease (CKD). Although the presence of CKD …

Hyperuricemia, ie increased serum uric acid (UA) concentration, is a common problem in
clinical practice. While there are clear guidelines concerning management of symptomatic …

Objective To evaluate the use of prospective screening for the HLA-B* 58: 01 allele to
identify Taiwanese individuals at risk of severe cutaneous adverse reactions (SCARs) …

Objectives The treat-to-target (T2T) concept has been applied successfully in several
inflammatory rheumatic diseases. Gout is a chronic disease with a high burden of pain and …

Abstract Three-dimensional (3D) nanostructured graphene can be used as a replacement or
enrichment material. This review presents the types of 3D graphene developed thus far, for …